Clinical transitions amid rapid expansion: a 16-year retrospective analysis of ultrasound-guided high-intensity Focused ultrasound (USgHIFU) for uterine fibroids and adenomyosis in Korea and the necessity for clinical standardization.

IF 3
Jae-Seong Lee, Kye-Hwa Lee
{"title":"Clinical transitions amid rapid expansion: a 16-year retrospective analysis of ultrasound-guided high-intensity Focused ultrasound (USgHIFU) for uterine fibroids and adenomyosis in Korea and the necessity for clinical standardization.","authors":"Jae-Seong Lee, Kye-Hwa Lee","doi":"10.1080/02656736.2026.2700021","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Since its introduction in 2010, Ultrasound-guided High-Intensity Focused Ultrasound (USgHIFU) has rapidly expanded in South Korea, despite the absence of widely accepted standardized clinical protocols. This study evaluated the long-term clinical outcomes of USgHIFU and proposed a standardized MRI-integrated treatment framework incorporating MRI-based planning, treatment verification, and structured follow-up.</p><p><strong>Methods: </strong>In this retrospective analysis, we included 2,992 patients (1,620 with uterine fibroids and 1,372 with adenomyosis) treated with USgHIFU between 2010 and 2025. Therapeutic efficacy was assessed using non-perfused volume (NPV) ratio, volume reduction rates (VRR), and reintervention rates. Long-term durability, defined as freedom from reintervention, was evaluated using Kaplan-Meier analysis in 476 patients with follow-up durations of 3-9.7 years.</p><p><strong>Results: </strong>Immediate post-treatment contrast-enhanced MRI demonstrated a mean NPV ratio of 86.5 ± 7.2%, with 94.2% of patients achieving an NPV ratio ≥ 80%. At 12 months, the mean VRRs were 77.4% and 61.4% for fibroids and adenomyosis, respectively. In the long-term follow-up subset (<i>n</i> = 476), volume reduction was maintained and then increased, reaching 78.8% for fibroids and 66.3% for adenomyosis at 3-9.7 years. Freedom from reintervention was 99.1% at 12 months, 98.4% at 3 years, and 97.6% at 9.7 years. No major complications were observed after implementation of the standardized treatment framework.</p><p><strong>Conclusion: </strong>Standardized USgHIFU treatment, achieving an NPV ratio ≥ 80%, is associated with sustained long-term clinical outcomes and a favorable safety profile. These findings support the clinical value of a standardized MRI-integrated treatment framework and may contribute to future clinical standardization of USgHIFU practice.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2700021"},"PeriodicalIF":3.0000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/02656736.2026.2700021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Since its introduction in 2010, Ultrasound-guided High-Intensity Focused Ultrasound (USgHIFU) has rapidly expanded in South Korea, despite the absence of widely accepted standardized clinical protocols. This study evaluated the long-term clinical outcomes of USgHIFU and proposed a standardized MRI-integrated treatment framework incorporating MRI-based planning, treatment verification, and structured follow-up.

Methods: In this retrospective analysis, we included 2,992 patients (1,620 with uterine fibroids and 1,372 with adenomyosis) treated with USgHIFU between 2010 and 2025. Therapeutic efficacy was assessed using non-perfused volume (NPV) ratio, volume reduction rates (VRR), and reintervention rates. Long-term durability, defined as freedom from reintervention, was evaluated using Kaplan-Meier analysis in 476 patients with follow-up durations of 3-9.7 years.

Results: Immediate post-treatment contrast-enhanced MRI demonstrated a mean NPV ratio of 86.5 ± 7.2%, with 94.2% of patients achieving an NPV ratio ≥ 80%. At 12 months, the mean VRRs were 77.4% and 61.4% for fibroids and adenomyosis, respectively. In the long-term follow-up subset (n = 476), volume reduction was maintained and then increased, reaching 78.8% for fibroids and 66.3% for adenomyosis at 3-9.7 years. Freedom from reintervention was 99.1% at 12 months, 98.4% at 3 years, and 97.6% at 9.7 years. No major complications were observed after implementation of the standardized treatment framework.

Conclusion: Standardized USgHIFU treatment, achieving an NPV ratio ≥ 80%, is associated with sustained long-term clinical outcomes and a favorable safety profile. These findings support the clinical value of a standardized MRI-integrated treatment framework and may contribute to future clinical standardization of USgHIFU practice.

快速扩张中的临床转变:韩国超声引导下高强度聚焦超声(USgHIFU)治疗子宫肌瘤和子宫腺肌症的16年回顾性分析及临床标准化的必要性。
背景:自2010年推出以来,超声引导的高强度聚焦超声(USgHIFU)在韩国迅速发展,尽管缺乏广泛接受的标准化临床方案。本研究评估了USgHIFU的长期临床结果,并提出了一个标准化的mri综合治疗框架,包括基于mri的计划、治疗验证和结构化随访。方法:在本回顾性分析中,我们纳入了2010年至2025年期间接受USgHIFU治疗的2992例患者(1620例子宫肌瘤患者和1372例bbb患者)。采用非灌注容积(NPV)比、容积缩小率(VRR)和再干预率评估治疗效果。使用Kaplan-Meier分析对476例随访时间为3-9.7年的患者进行长期耐久性评估,定义为不受再干预。结果:治疗后立即增强MRI显示平均NPV率为86.5±7.2%,94.2%患者达到NPV率≥80%。12个月时,肌瘤和子宫腺肌症的平均vrr分别为77.4%和61.4%。在长期随访亚组(n = 476)中,肌瘤的体积缩小维持后增加,在3-9.7年时肌瘤的体积缩小率为78.8%,子宫腺肌症的体积缩小率为66.3%。12个月时再干预率为99.1%,3年时为98.4%,9.7年时为97.6%。标准化治疗框架实施后,无重大并发症发生。结论:标准化的USgHIFU治疗,实现NPV率≥80%,与持续的长期临床结果和良好的安全性相关。这些发现支持了标准化mri综合治疗框架的临床价值,并可能有助于未来USgHIFU实践的临床标准化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书